Shearman & Sterling represented ContraFect Corporation, a Yonkers, NY-based, privately held infectious disease company, in its license agreement with Trellis Bioscience LLC. According to the license agreement, Trellis Bioscience granted ContraFect Corporation an exclusive worldwide license for the development and commercialization of preclinical fully-human antibodies discovered using Trellis’ CellSpot™ technology for use in the treatment and prevention of influenza.
Trellis Bioscience is a private, venture-funded antibody discovery company formed around a breakthrough discovery platform, called CellSpot™, capable of isolating therapeutic grade antibodies directly from the blood cells of humans.
ContraFect Corporation is an IND-stage biotechnology company focused on development and commercialization of protein and antibody products for life threatening bacterial and viral infectious diseases, particularly those used in hospital-based settings.
The Shearman & Sterling team included partner Richard Hsu (Palo Alto-Intellectual Property Transactions) and associate Benjamin Petersen (Palo Alto-Intellectual Property Transactions).